

李德章

Te-Chang Lee, Ph.D.



現職： 中央研究院生物醫學科所特聘員
臺灣人體生物資料庫代表

網站： <https://www.ibms.sinica.edu.tw/te-chang-lee/>

學歷

輔仁大學生物系士 (1970-1974)
國立臺灣大學動物研究所碩士 (1974-1976)
國立臺灣大學生化研究所博士 (1976-1980)

經歷

中央研究院學術諮詢總會執行秘書兼及儀器事務處代理處長 (2012.01-2016.09)
國立中醫藥研究所長 (2007.09-2009.08)
國立陽明大學副校長 (2004.04-2005.01)
國立陽明大學生命科院長 (2001.02-2004.04)
中央研究院生物醫學科所代所長 (1996 & 2001)
中央研究院生物醫學科所副所長 (1994.03-1997.09)

獎項及榮譽

1. 第 13 屆永信李天德醫藥科技獎－卓越醫藥科技獎 (2017)
2. 教育部第 48 屆學術獎 (2004)
3. 國科會特約研究人員 (1996、1999)
4. 國科會傑出研究獎 (1988、1990、1992、1994)
5. 教育部青年研究發明獎助金研究著作甲等獎 (1979)

研究成果 (Since 2019)

1. Pidugu VK, Wu MM, Yen AH, Pidugu HB, Chang KW, Liu CJ and **Lee TC*** (2019) IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling. *Oncogene*, 38: 3232-3247.
2. Chang SM, Jain V, Chen TL, Patel AS, Pidugu HB, Lin YW, Wu MH, Huang JR, Wu HC, Shah A, Su TL* and **Lee TC*** (2019) Design and synthesis of 1,2-bis(hydroxymethyl)pyrrolo[2,1-*a*]phthalazine hybrids as potent anticancer agents that inhibit angiogenesis and induce DNA interstrand cross-links. *J Med Chem*, 62: 2404-2418.
3. Lin MS, Hong TM, Chou TH, Yang SC, Chung WC, Weng CW, Tsai ML, Cheng TJ, Chen JJW, **Lee TC**, Wong CH, Chein RJ, Yang PC (2019) 4(1H)-quinolone derivatives overcome acquired resistance to antimicrotubule agents by targeting the colchicine site of β -tubulin. *Eur. J. Med. Chem.*, 181: 111584 (online).

4. Pidugu VK, Pidugu HB, Wu MM, Liu CJ and **Lee TC*** (2019) Emerging functions of human IFIT proteins in cancer. *Front. Mol. Biosci.*, 6: 148. (A review)
5. Hu WC, Teo WH, Huang TF, **Lee TC** and Lo JF (2020) Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer initiating cells. *Front. Oncol.*, 10: 463.
6. Patel AS, Jain V, Rao VN, Lin YW, Shah A, Lai KC, Su TL* and **Lee TC*** (2020) Design, synthesis and antitumour evaluation of pyrrolo[1,2-*f*]-phenanthridine and dibenzo[*f,h*]pyrrolo[1,2-*b*]isoquinoline derivatives. *Eur. J. Med. Chem.*, 202:112516.
7. Regmi P, Lai KC, Liu CJ and **Lee TC*** (2020) SAHA overcomes 5-FU resistance in IFIT2-depleted oral squamous cell carcinoma cells. *Cancers*, 12: E3527.
8. Wei CY, Yang JH, Yeh EC, Tsai MF, Kao HJ, Lo CZ, Chang LP, Lin WJ, Hsieh FJ, Belsare S, Bhaskar A, Su MW, **Lee TC**, Lin YL, Liu FT, Shen CY, Li LH, Chen CH, Wall JD, Wu JY and Kwok PY (2021) Genetic profiles of 103,106 individuals in the Taiwan Biobank provide insights into the health and history of Han Chinese. *Gen. Med.*, 6: 10.
9. Wu MM, Hsieh FI, Hsu LI, **Lee TC**, Chiou HY and Chen CJ (2021) GT-repeat polymorphism in the HO-1 gene promoter is associated with risk of liver cancer: A follow-up study from arseniasis-endemic areas in Taiwan. *J. Clin. Med.*, 10: 1489.
10. Chen TL, Patel AS, Jain V, Kuppusamy R, Lin YW, Hou MH, Su TL* and **Lee TC*** (2021) Discovery of oral anticancer 1,2-bis(hydroxymethyl)benzo[*g*]pyrrolo[2,1-*a*]phthalazine hybrids that inhibit angiogenesis and induce DNA cross-links. *J. Med. Chem.*, 64: 12469-12486.